Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The AACR's Cancer Progress Report 2026 spotlights a wave of new therapies, AI tools, and promising cancer vaccines — but raises concerns about proposed federal rules that could let politics override science in research funding. A dozen FDA approvals, mRNA vaccine milestones, and AI-powered drug discovery headline the wins. The big worry? A proposed grant-making overhaul that could sideline peer review.
The American Association for Cancer Research (AACR) released its annual Cancer Progress Report, and it tells two stories: remarkable scientific momentum and a looming threat to the funding that makes it all possible. On the wins side, the FDA approved 12 new anti-cancer therapies in the past year alone — including the first immune checkpoint inhibitor for ovarian cancer, the first CAR T-cell therapy for marginal zone lymphoma, and a first-of-its-kind wearable device for pancreatic cancer. mRNA cancer vaccines also showed durable promise in melanoma, triple-negative breast cancer, and pancreatic cancer trials.
AI is rapidly becoming a force multiplier in oncology — from pathology review to drug discovery. One AI model screened 10,000 human proteins against more than 500 million compounds, surfacing over 2 million drug candidates. GLP-1 drugs remain a hot topic in oncology circles, though evidence on their cancer-prevention potential is still mixed.
By the Numbers
Why it matters: The AACR is raising a bipartisan alarm: a proposed federal rule could allow political appointees to override peer review in grant decisions — potentially defunding critical research based on ideology rather than scientific merit. Congress has temporarily blocked it until December 2026, but the clock is ticking.
